Page last updated: 2024-12-11

triarachidonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID9545801
CHEBI ID147308
SCHEMBL ID1502514
MeSH IDM0155749

Synonyms (23)

Synonym
23314-57-0
tg(20:4/20:4/20:4)
LMGL03011840
tg(20:4(5z,8z,11z,14z)/20:4(5z,8z,11z,14z)/20:4(5z,8z,11z,14z))
1,2,3-tri-(5z,8z,11z,14z-eicosatetraenoyl)-glycerol
triarachidonin
1,2,3-tri-(5z,8z,11z,14z-icosatetraenoyl)-glycerol
tag(20:4n6/20:4n6/20:4n6)
CHEBI:147308
tag(20:4(5z,8z,11z,14z),20:4(5z,8z,11z,14z),20:4(5z,8z,11z,14z))
SCHEMBL1502514
1,2,3-tri-[(cis,cis,cis,cis)-5,8,11,14-eicosatetraenoyl]-glycerol
tg(20:4w6/20:4w6/20:4w6)
tracylglycerol(20:4w6/20:4w6/20:4w6)
tag(20:4w6/20:4w6/20:4w6)
tg(20:4n6/20:4n6/20:4n6)
1-arachidonoyl-2-arachidonoyl-3-arachidonoyl-glycerol
tri-5(z),8(z),11z(),14(z)-eicosatetraenonin
tracylglycerol(20:4n6/20:4n6/20:4n6)
2,3-bis[[(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoyl]oxy]propyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
CS-0134307
PD044126
HY-131423

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Trilinolenin (18:3; omega-3) was toxic only after prolonged incubation."( Toxicity of polyunsaturated fatty acid esters for human monocyte-macrophages: the anomalous behaviour of cholesteryl linolenate.
Carpenter, KL; Hardwick, SJ; Hird, R; Law, NS; Marchant, CE; Mitchinson, MJ; Van Der Veen, C, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triacylglycerol 60:12A triglyceride in which the three acyl groups contain a total of 60 carbons and 12 double bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
De Novo Triacylglycerol Biosynthesis TG(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))513

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]